CMMI has made an important change to the Enhancing Oncology Model (EOM) for a second enrollment period beginning July 1, 2025 (Performance Period 4). The change resets the neutral zone between the benchmark and target price, rather than at 98% of the benchmark.
This change is a major benefit for EOM participants, as it makes success under the program, as well as lower premiums for downside risk (stop loss) insurance, more attainable.
https://www.cms.gov/priorities/innovation/media/document/eom-payment-methodology
